Saxagliptin Tablet Coating Stabilization Against N-Formyl Impurities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Saxagliptin tablets face degradation issues due to the formation of N-formyl impurities and gelatin crosslinking during manufacturing and storage, primarily caused by formic acid and its derivatives, which affect the stability and efficacy of the drug product.
Innovation Solution
Incorporating an amine compound such as glycine, histidine, arginine, ethanolamine, or diethanolamine into the coating layer of saxagliptin tablets, in combination with poly(ethylene glycol) and poly(vinyl alcohol), to prevent or reduce the formation of N-formyl adducts by reacting with formic acid and its derivatives, thereby stabilizing the active pharmaceutical ingredient.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If saxagliptin is formulated with Opadry II white as the second coating, then the formation of cyclic amidine (CA) and its reaction product DKP is reduced, but N-formyl adduct (NFA) impurity is observed during the process of preparing the second coating
Solution Approach 1:
An amine compound is introduced as an intermediary substance between saxagliptin and formylating species. This amine compound reacts with formic acid and its derivatives to form stable amine-formate salts, preventing the formylating species from reacting with saxagliptin and forming N-formyl adduct impurities
Solution Approach 2:
The harmful formic acid and formylating species that would normally cause N-formyl adduct formation are converted into beneficial amine-formate salts through reaction with the amine compound. This transformation eliminates the harmful effect while creating a stable, non-reactive species
2Ease of manufacture
If formic acid and its derivatives are present in the coating layer, then the coating material can be processed, but N-formyl impurities and gelatin crosslinking occur during manufacturing and storage
Solution Approach 1:
The amine compound is incorporated into the coating layer in advance before the coating is applied to the tablet. This preliminary presence allows the amine compound to preemptively react with formic acid and formylating species, preventing N-formyl impurity formation and gelatin crosslinking during subsequent manufacturing and storage
Solution Approach 2:
The amine compound serves as a protective intermediary within the coating layer, intercepting formic acid and its derivatives before they can cause degradation. This intermediary reaction creates stable amine-formate salts that maintain coating processability while preventing harmful side reactions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of amine compounds effectively inhibits the formation of N-formyl impurities and gelatin crosslinking, enhancing the long-term stability and shelf-life of saxagliptin tablets by scavenging formyl species and maintaining the drug's potency.
Implementation Method 1
The primary amine of saxagliptin is formylated by the reaction of saxagliptin with a formylating species such as formic acid, formic acid esters, formates, formic acid anhydrides and/or formaldehyde
Implementation Method 2
The formulations of the present invention can prevent or reduce formylation of saxagliptin during the manufacturing process and/or during shelf-life storage
Data Source
Figure 1
Figure 2A~2B
AI summary
The present invention relates to solid, semisolid, or liquid formulations comprising amine compounds that prevent or reduce formic acid and/or formyl species generation in the dosage form during the manufacturing process and/or during shelf -life storage. The formulations of the present invention prevent or reduce formation of N- formyl impurities (and gelatin crosslinking) during the manufacturing process and/or during shelf -life storage.